Nlrp3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NLRP3 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of NLRP3 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
Protein Name: NLRP3 (NALP3, Cryopyrin)
Gene: NLRP3
UniProt ID: Q9N2R8
Molecular Weight: 118 kDa
Subcellular Localization: Cytoplasm, also reported in nucleus
Protein Family: NLR (NOD-like Receptor) Family
NLRP3 has a characteristic tripartite domain architecture:
The NACHT domain containsWalker A (P-loop) and Walker B motifs for ATP binding/hydrolysis, essential for inflammasome assembly[1].
NLRP3 functions as a pattern recognition receptor:
Activated NLRP3 inflammasome leads to:
NLRP3 also participates in:
NLRP3 contributes to AD pathogenesis:
Therapeutic targeting of NLRP3 may reduce neuroinflammation and slow progression.
In PD, NLRP3 plays detrimental roles:
NLRP3 inflammasome in ALS:
Several inhibitors in development:
Indirect targeting through IL-1:
Martinon F, et al. (2002). "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β." Mol Cell. 10(2):417-426. DOI:10.1016/S1097-2765(0200599-3[1:1]
Heneka MT, et al. (2013). "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice." Nature. 493(7434):674-678. [DOI:10.1038/nature11729^2]
Sun L, et al. (2020). "NLRP3 deficiency attenuates Parkinson's disease via autophagy." Brain Res. 1727:146530. [DOI:10.1016/j.brainres.2019.146530^3]
Johansson J, et al. (2020). "NLRP3 inflammasome in ALS - a promising therapeutic target?" Pharmacol Ther. 212:107553. [DOI:10.1016/j.pharmthera.2020.107553^4]
The study of Nlrp3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Martinon F, et al. (2002). "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β." Mol Cell. 10(2):417-426. DOI:10.1016/S1097-2765(0200599-3 ↩︎ ↩︎
Heneka MT, et al. (2013). "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice." Nature. 493(7434):674-678. DOI:10.1038/nature11729 ↩︎
Sun L, et al. (2020). "NLRP3 deficiency attenuates Parkinson's disease via autophagy." Brain Res. 1727:146530. DOI:10.1016/j.brainres.2019.146530 ↩︎
Johansson J, et al. (2020). "NLRP3 inflammasome in ALS - a promising therapeutic target?" Pharmacol Ther. 212:107553. DOI:10.1016/j.pharmthera.2020.107553 ↩︎